Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kriptic Pharmaceuticals Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and 1 distinct art unit. This indicates that the company's current prosecution efforts are focused within a specialized technical group. The concentration in 1 distinct art unit suggests that the pending applications are closely related within the pharmaceutical field.
WEHBE, ANNE MARIE SABRINA is the busiest examiner for the company. This examiner is handling 1 pending office action. Since there are 2 distinct examiners for 2 pending actions, the workload is distributed across the examination staff. Both examiners are working within the same art unit, which should lead to a relatively consistent application of technical standards and prior art across the portfolio. This profile allows the company to manage its prosecution strategy by focusing on the specific tendencies of this 1 distinct art unit while addressing the individual feedback from the 2 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 1 | 57.2% | +43.4% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16611172 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Lung Cancer in a HLA-A*0201-Positive Never-Smoker or Light-Former Smoker Patient | COFFA, SERGIO | 18d overdue |
| 18744060 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18744060 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert | WEHBE, ANNE MARIE SABRINA | — | §102§103DP | Non-Final OA | — | Pending | Jun 14, 2024 |
| 16611172 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Lung Cancer in a HLA-A*0201-Positive Never-Smoker or Light-Former Smoker Patient | COFFA, SERGIO | 1658 | §112 | Final Rejection | 18d overdue | Pending | Nov 05, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial